Sculptra Aesthetic
U.S. FDA PMA P030050/S002; this U.S. record does not establish Korean authorization or clinic availability.
Key specs
- Product class
- injectable poly-L-lactic acid (PLLA)
- Plan and follow-up
- individualized after examination
Injectable PLLA · individualized decision guide
Sculptra (PLLA) in Seoul
Sculptra Aesthetic is an injectable poly-L-lactic acid (PLLA) dermal implant in the U.S. FDA PMA record. It is not hyaluronic-acid filler. Whether it fits a concern, and the treatment and follow-up plan, require individual assessment.
Board-Certified
Dermatologist
AAD International Fellow
IFAAD
- Duration
- Set after assessment
- Sessions
- No universal course
- Downtime
- Varies by plan
Reviewed personally by Dr. SangYoul Yun
Board-certified Dermatologist · AAD International Fellow (IFAAD) · IFAAD-verified
01
Sculptra Overview
Sculptra is considered for gradual correction rather than immediate, reversible filling. Treatment areas, session count, response timing, durability, availability, and price are not universal clinic facts; each requires individual assessment or confirmation after examination, with limitations and risks discussed first.
Best for
- Whether a gradual PLLA approach matches the actual contour concern
- Choosing between PLLA, hyaluronic-acid filler, and skin-quality treatment
- Understanding delayed change, limits, and the absence of an immediate result promise
- Planning follow-up when travelling to Seoul
Suited for
- People with an anatomically appropriate concern confirmed by examination
- People who accept gradual and variable change rather than an immediate correction
- People who understand that the plan cannot be copied from another patient
- People able to complete follow-up and report delayed symptoms after returning home
- Duration
Set after assessment
- Sessions
No universal course
- Downtime
Varies by plan
- Peak result
Reassessed over time
02
Sculptra Results Over Time
Immediately after injection
Swelling can make the area look temporarily different and should not be treated as the final result.
During follow-up
Change is gradual and variable; response and adverse effects are reassessed before any additional treatment.
Longer term
No universal peak date, duration, or maintenance interval is promised for an individual patient or treatment area.
Immediately after injection
Swelling can make the area look temporarily different and should not be treated as the final result.
During follow-up
Change is gradual and variable; response and adverse effects are reassessed before any additional treatment.
Longer term
No universal peak date, duration, or maintenance interval is promised for an individual patient or treatment area.
03
Devices Used for Sculptra
04
How Sculptra Works
01
Examine the concern and distinguish volume or contour change from laxity and skin-quality concerns.
02
Confirm product identity and explain how injectable PLLA differs from hyaluronic-acid filler and other alternatives.
03
Review the U.S. labeled indication separately from the proposed treatment area and from Korean authorization or clinic availability.
04
Discuss material injection risks, delayed reactions, alternatives, and the limits of correction before consent.
05
Set the treatment and follow-up plan individually, reassessing response before any additional treatment.
01
Examine the concern and distinguish volume or contour change from laxity and skin-quality concerns.
02
Confirm product identity and explain how injectable PLLA differs from hyaluronic-acid filler and other alternatives.
03
Review the U.S. labeled indication separately from the proposed treatment area and from Korean authorization or clinic availability.
04
Discuss material injection risks, delayed reactions, alternatives, and the limits of correction before consent.
05
Set the treatment and follow-up plan individually, reassessing response before any additional treatment.
“Injectables and energy devices are performed by physicians — never delegated to non-physician staff. The clinic is led by a board-certified dermatologist.”
05
Sculptra Aftercare & Recovery
After treatment
Follow the product- and injector-specific instructions supplied after the procedure; do not substitute a generic online schedule.
If symptoms worsen
Seek prompt clinical assessment for increasing pain, color change, visual symptoms, infection signs, or a concerning delayed lump or nodule.
Before further treatment
Reassess response and complications before deciding whether another treatment is appropriate.
After treatment
Follow the product- and injector-specific instructions supplied after the procedure; do not substitute a generic online schedule.
If symptoms worsen
Seek prompt clinical assessment for increasing pain, color change, visual symptoms, infection signs, or a concerning delayed lump or nodule.
Before further treatment
Reassess response and complications before deciding whether another treatment is appropriate.
06
FAQ
What is Sculptra Aesthetic?
The U.S. FDA PMA record identifies Sculptra Aesthetic as an injectable dermal implant containing poly-L-lactic acid. The U.S. record has a defined indication and does not by itself establish Korean authorization, clinic availability, or suitability for another treatment area.
Is Sculptra the same as hyaluronic-acid filler?
No. It is an injectable PLLA implant, not hyaluronic-acid filler. The onset, correction strategy, reversibility discussion, and follow-up are different, so the choice should follow examination rather than a universal comparison claim.
How many sessions are needed, and when is the result visible?
This page does not publish one fixed course or peak date. The proposed area, baseline concern, response, prior treatment, and ability to follow up should determine whether treatment proceeds and whether any additional session is appropriate.
How long does Sculptra last?
Published study follow-up does not create a guaranteed duration for an individual patient or treatment area. Durability varies, and a maintenance interval should not be promised before response is assessed.
What risks should be discussed?
U.S. physician labeling lists injection-site swelling, tenderness, redness, pain, bruising, bleeding, papules or nodules, inflammation, and infection risk, and warns against injection into blood vessels. Personal risk and urgent warning signs require clinician-specific consent.
How should an international patient plan follow-up?
Plan for possible visible recovery and agree on local or remote escalation before treatment. Delayed lumps, nodules, inflammation, increasing pain, or color change should not wait for a future trip to be assessed.
Notice
Tell the dermatologist at consultation if any of the following apply.
- Do not use in a person with hypersensitivity to a product component or a known history or susceptibility to keloid formation or hypertrophic scarring, per U.S. labeling.
- Defer treatment at a site with active inflammation or infection until it has resolved and is controlled.
- Pregnancy, breastfeeding, bleeding risk, immune or connective-tissue conditions, prior implants, and prior procedures require individual review because evidence or suitability may be limited.
- Do not proceed when adequate consent, recovery time, or follow-up cannot be arranged.
Session summary & comparison
| Item | Details |
|---|---|
| Duration | Set after assessment |
| Sessions | No universal course |
| Downtime | Varies by plan |
| Peak result | Reassessed over time |
For your visit
- Allow for possible swelling, tenderness, redness, pain, or bruising when planning flights and fixed events.
- Agree on how early concerns and delayed lumps or nodules will be reviewed after returning home.
- Do not assume that one Seoul visit completes an appropriate plan; the need for further treatment is decided after reassessment.
- If follow-up cannot be arranged, deferring treatment or choosing a different option may be safer.
07
References
The clinical claims on this page — device specs, efficacy timelines, safety profile — are supported by the primary sources below. Each citation links to the original paper or regulatory record.3 refs
- [1]Sculptra Aesthetic PMA Supplement S002. U.S. Food and Drug Administration (2009).
- [2]Sculptra Aesthetic: U.S. Physician Labeling. U.S. Food and Drug Administration (2009).
- [3]Injectable Poly-L-Lactic Acid Versus Human-Based Collagen Implant for Nasolabial Fold Wrinkles. Journal of the American Academy of Dermatology (2010).
Related procedures
ProcedureFace Filler in Seoul | Hyaluronic Acid Dermal FillerHyaluronic acid (HA) dermal filler in Gangnam — anatomy-based product selection across Juvéderm and Belotero, the two brands Dr. Yun uses in clinic.
ProcedureSkin Booster in Seoul | Product Identity & Evidence GuideThis page is retained to explain product identity, evidence limits, and questions to verify before planning. It does not confirm clinic availability, variants, a protocol, a price, or an outcome timeline.
G
ProcedureGLP-1 Face & Body Recovery in Seoul"Ozempic face" is an informal term for facial changes noticed after weight loss, such as volume loss, looser contours, or skin-quality change. It is not a diagnosis, and treatment starts by identifying the concern rather than choosing a package.
Evidence & comparison guides
Need another answer before deciding?
You do not need to read every guide. Open the question that still matters to your decision.
Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.
Next Step